Peter P. Phildius

Medisystems Corp. manufactures and distributes medical devices for dialysis and blood related treatments. Its products include Streamline and ReadySet blood tubing sets, MasterGuard and ButtonHole needle sets, safety accessories and access management tools. The company was founded on March 22, 1993 and is headquartered in Lawrence, MA.

Vasca, Inc. develops access and related technologies. It manufactures and markets life site hemodialysis access system technologies to improve the quality of patient care in the United States. The company was founded by Jeffrey H. Burbank in April 1996 and is headquartered in Tewksbury, MA.

Fresenius Medical Care Holdings, Inc. provides kidney dialysis services and renal care products. It offers specialty pharmacy and laboratory services as well as manufacturing and distributing dialysis equipment, disposable products, and renal pharmaceuticals. The company was founded in 1996 and is headquartered in Waltham, MA.

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.

Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada.

Cerapedics, Inc. engaged in the provision of developing and commercializing novel osteobiologic products. It offers i-FACTOR Bone Graft, an advanced biologic that supported with level I evidence, and provides benefit ratio. The company was founded by Andrew J. Tofe and is headquartered in Westminster, CO.

LifeCell Corp. develops and markets tissue repair products. The firm focuses on reconstructive, urogynecologic and orthopedic surgical procedures. Its products include alloderm, strattice, graft jacket, allocraftdbm and repliform. The company was founded in 1986 and is headquartered in Branchburg, NJ.

Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA.

Orthovita, Inc. engages in the development and commercialization of synthetic biologically-active tissue engineering products for restoration of the human skeleton. The company was incorporated in 1992 and is headquartered in Malvern, PA.

Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY.

Arteaus Therapeutics LLC develops therapies for migraine prevention. The company was founded by Dave Grayzel and Scott C. Chappel on July 15, 2011 and is headquartered in Cambridge, MA.

DFINE, Inc.engages in the development and commercialization of medical device system for treating vertebral compression fractures. The company was founded by John H. Shadduck and Csaba Truckai in 2004 and is headquartered in South Jordan, UT.

LBO France Gestion SAS (LBO France) is one of the oldest independent private equity firms in France. Established in 1985, the firm manages leveraged buyout transactions through their small-cap, mid-cap and real estate funds. Headquartered in Paris, LBO France primarily targets French firms or companies which are based or which transact most of their business in France.

Qpid Health, Inc. provides health record acceleration software and intelligence solutions. It develops clinical insights software for use by hospitals and medical groups. The firm’s QPID solution uses natural language processing and proprietary tools to improve how clinical and administrative users can have access to information stored in electronic health records. The company was founded by Michael Zalis and Mitchell Harris in 2011 and is headquartered in Boston, MA.

Truveris, Inc. provides health information technology services. It products include TruGuard is a proprietary technology validates claim payment accuracy, ensures regulatory compliance, and manages pharmacy spend. The company was founded by Leon Greene, Anthony J. Loiacono, Thomas Andrew Staloch, Kristin Begley and Justin E. Greene in 2008 and is headquartered in New York, NY.

Phylos, Inc. provides biopharmaceutical research and manufacturing services. The company is headquartered in Lexington, MA.

Stilla Technologies SA operates as a biotechnology company that focuses on the development genetic tests. It provides crystal digital PCR, a next-generation technology for absolute quantification of nucleic acids. The company was founded by Remi Dangla, Etienne Fradet and Clement Gay in 2013 and is headquartered in Villejuif, France.

Tribvn Healthcare SAS engages in macroscopic imaging and development of software for digital pathology. It offers CaloPix, teleSlide, Imange analysis, Mocro by TRINVN and, Service provision. The firm operates in the following business segments: Diagnostic, Academic research, Teaching, Pharma & Biotech and, telemedicine. The company was founded in 1996 and is headquartered in Chatillon, France.

Novadiscovery SAS develops mathematical model and artificial intelligence solutions for the healthcare sector. It offers risk management analytic tools for medical research programs and clinical trials. The company was founded by Fr?d?ric Cogny, Jean-Pierre Boissel, and Fran?ois-Henri Boissel in 2010 and is headquartered in Lyon, France.

EG 427 is a French biotechnology company that specializes in gene therapy. The location of the company is unknown. The company was founded by Alberto Epstein, François Giuliano, and Philippe O. Chambon, with Philippe O. Chambon serving as CEO since incorporation.

FeetMe SAS develops insoles that map foot pressure in real time for diabetic patients. Its insoles are made of pressure sensors that allow patients and doctors to visualize a detailed pressure map of the feet, as well as provide warning to patients if a change in the plantar pressure is detected. The company was founded by Julien Mercier and Alexis Mathieu in 2013 and is headquartered in Versailles, France.

Emphasys Medical, Inc., a medical technology company, focuses on developing and commercializing minimally invasive therapeutic devices for the treatment of patients with emphysema and other breathing disorders. It offers Zephyr Endobronchial Valve system, which is designed to block air from passing through the opening in the lung and into the chest cavity, resulting in the reduction or elimination of airflow through the leak to allow the tissue to heal. The company offers its products through distributors and dealers in Europe, Australia, Hong Kong, and Singapore. Emphasys Medical was founded in 2000 and is based in Redwood City, CA. Emphasys Medical, Inc. operates as a subsidiary of Pulmonx Corp.